持续性房颤导管消融后复发模式及其对生活质量和医疗利用的影响
该研究为CAPLA试验的事后分析,纳入333例症状性持续性房颤患者,随机接受肺静脉隔离联合后壁隔离或单纯肺静脉隔离。12个月随访时46.2%患者复发,其中63%为阵发性、37%为持续性;持续性复发者房颤负荷更高、医疗利用更多、生活质量改善更少。
要点
- 持续性房颤消融后复发多表现为阵发性,与消融策略无关。
- 持续性复发者房颤负荷更高、医疗利用更多、生活质量改善更少。
- 复发类型和房颤负荷可作为持续性房颤消融试验的重要终点。
核心结论
- 持续性房颤导管消融后复发以阵发性为主,且不因消融策略而异。
- 持续性复发与更高房颤负荷、更多医疗利用及抗心律失常药物使用相关。
- 复发类型和房颤负荷或可作为持续性房颤消融临床试验的重要终点。
研究设计与样本
- CAPLA研究的事后分析,为国际多中心随机对照试验。
- 纳入症状性持续性房颤患者,随机接受肺静脉隔离联合后壁隔离或单纯肺静脉隔离。
- 监测方式包括每日两次单导联心电图、植入设备监测或每三个月动态心电图。
主要发现
- 333例患者中154例(46.2%)在12个月随访时复发,中位年龄67.3岁,女性占28%。
临床怎么用
- 消融后复发多为阵发性,临床可据此调整监测与随访策略。
- 持续性复发者房颤负荷高、医疗利用多,需加强管理和抗心律失常药物使用评估。
- 生活质量改善与是否复发及复发类型相关,可作为患者沟通要点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patterns of atrial fibrillation (AF) recurrence post-catheter ablation for persistent AF (PsAF) are not well described. This study aimed to describe the pattern of AF recurrence seen following catheter ablation for PsAF and the implications for healthcare utilization and quality of life (QoL). METHODS: This was a post-hoc analysis of the CAPLA study, an international, multicentre study that randomized patients with symptomatic PsAF to pulmonary vein isolation plus posterior wall isolation or pulmonary vein isolation alone. Patients underwent twice daily single lead ECG, implantable device monitoring or three monthly Holter monitoring. RESULTS: 154 of 333 (46.2%) patients (median age 67.3 years, 28% female) experienced AF recurrence at 12-month follow-up. Recurrence was paroxysmal in 97 (63%) patients and persistent in 57 (37%). Recurrence type did not differ between randomization groups (P = .508). Median AF burden was 27.4% in PsAF recurrence and .9% in paroxysmal AF (PAF) recurrence (P < .001). Patients with PsAF recurrence had lower baseline left ventricular ejection fraction (PsAF 50% vs. PAF 60%, P < .001) and larger left atrial volume (PsAF 54.2 ± 19.3 mL/m² vs. PAF 44.8 ± 11.6 mL/m², P = .008). Healthcare utilization was significantly higher in PsAF (45 patients [78.9%]) vs. PAF recurrence (45 patients [46.4%], P < .001) and lowest in those without recurrence (17 patients [9.5%], P < .001). Patients without AF recurrence had greater improvements in QoL as assessed by the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire (Δ33.3 ± 25.2 points) compared to those with PAF (Δ24.0 ± 25.0 points, P = .012) or PsAF (Δ13.4 ± 22.9 points, P < .001) recurrence. CONCLUSIONS: AF recurrence is more often paroxysmal after catheter ablation for PsAF irrespective of ablation strategy. Recurrent PsAF was associated with higher AF burden, increased healthcare utilization and antiarrhythmic drug use. The type of AF recurrence and AF burden may be considered important endpoints in clinical trials investigating ablation of PsAF.
引用
- Crowley R, Chieng D, Sugumar H, et al. Catheter ablation for persistent atrial fibrillation: patterns of recurrence and impact on quality of life and health care utilization. Eur Heart J. 2024. PMID: 38759110. doi:10.1093/eurheartj/ehae291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。